Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 4Lymphoma, T-Cell, Cutaneous 3Mycosis Fungoides 2Lymphoma, Large-Cell, Anaplastic 2Hodgkin Disease 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Glioma 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 48Filgrastim 21fludarabine phosphate 19Rituximab 19Etoposide 19Peripheral Blood Stem Cell Transplantation 17fludarabine 16Prednisone 16Vincristine 15Cytarabine 12Doxorubicin 11blinatumomab 8Methotrexate 8Dexamethasone 8Cyclosporine 8Bortezomib 8venetoclax 7Vorinostat 7Paclitaxel 7Melphalan 7Lenalidomide 7Calcium Dobesilate 7Biopsy 7Specimen Handling 6Radiotherapy 6Indium 6tanespimycin 5aldesleukin 5Tacrolimus 5Inotuzumab Ozogamicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Burkitt Lymphoma × Lactones × Clear all
NCT01897012 2019-01-28

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
26 enrolled
Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡